Metastatic Breast Cancer Coexisting With HER-2 Amplification and EGFR Exon 19 Deletion Benefits From EGFR-TKI Therapy: A Case Report

Background: Patients with different molecular subtypes of breast cancers have different recurrence risks and prognoses. Clinical support and evidence to guide management are absent for patients with breast cancer coexisting with HER-2 amplification and EGFR mutations. Case presentation: We report a...

Descripción completa

Detalles Bibliográficos
Autores principales: Jing, Wei, Ma, Jie-Tao, Han, Cheng-Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274020/
https://www.ncbi.nlm.nih.gov/pubmed/32547945
http://dx.doi.org/10.3389/fonc.2020.00771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274020/
https://www.ncbi.nlm.nih.gov/pubmed/32547945
http://dx.doi.org/10.3389/fonc.2020.00771

Ejemplares similares